Skip NavigationSkip to Content
Return Return to Search Results

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

  1. Author:
    Yamashita, T. E.
    Phair, J. P.
    Munoz, A.
    Margolick, J. B.
    Detels, R.
    O'Brien, S. J.
    Mellors, J. W.
    Wolinsky, S. M.
    Jacobson, L. P.

  2. Author Address

    Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Room E7006, Baltimore, MD 21205 USA. Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA. Northwestern Univ, Sch Med, Chicago, IL USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. NCI, Lab Genom Divers, Frederick, MD 21701 USA. Univ Pittsburgh, Pittsburgh, PA USA. Vet Affairs Med Ctr, Pittsburgh, PA USA. Jacobson LP Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Room E7006, Baltimore, MD 21205 USA.
    1. Year: 2001
  2. Journal: Aids
    1. 15
    2. 6
    3. Pages: 735-746
  4. Type of Article: Article
  1. Abstract:

    Objectives: To evaluate prior antiretroviral therapy experience and host characteristics as determinants of immunologic and virologic response to highly active antiretroviral therapy (HAART). Methods: We studied 397 men from the Multicenter AIDS Cohort Study (MACS) who initiated HAART between October 1995 and March 1999. CD4 cell count and HIV-1 RNA responses to HAART were measured at the first visit following HAART (shortterm) and extending from the first visit to approximately 33 months after HAART (longterm). Prior antiretroviral experience was classified into three groups based on antiretroviral therapy use during the 5 years prior to HAART. Age, race and host genetic characteristics also were assessed for their effects on treatment response. Results: Better short- and long-term CD4 cell and HIV-1 RNA responses were observed in the treatment- naive users. Intermittently and consistently experienced users did not significantly differ in response. Whereas race did not independently affect response, among those initiating HAART with > 400 x 10(6) CD4 cells/l, younger age and the Delta 32 CCR5 genotype were associated with a better short-term CD4 cell response. There was a suggestion that having the protective CCR5 genotype also was associated with a better long-term CD4 cell response. Conclusion: Immunologic and virologic response to HAART was stronger in individuals who had no prior experience with the antiretroviral therapy agents subsequently included in their initial HAART regimen. Age, level of immune competence and immunogenetics appeared to play a role in the subsequent immune reconstitution Following use of highly effective HIV therapy. (C) 2001 Lippincott Williams & Wilkins.

    See More

  1. Keywords:

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel